GlassScriptPhysician profile
Ryan R Byrne
NPI 1063619773
$1,753.95
in general payments reported to CMS, 2019-2025
20 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $315 · 2023: $317 · 2024: $241 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $191.46 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $186.92 | 2022-2025 | Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $142.67 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $125.52 | 2024-2025 | Trintellix |
| Alkermes, INC. | $114.65 | 2023-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.54 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $108.70 | 2022-2025 | Austedo Xr, Austedo |
| Abbvie INC. | $97.14 | 2024-2025 | |
| Axsome Therapeutics, INC. | $95.22 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $90.64 | 2022-2023 | Ingrezza |
| Collegium Pharmaceutical, INC. | $88.40 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $72.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.73 | 2024-2025 | Cobenfy |
| Corium, LLC | $61.08 | 2025 | Azstarys |
| Tris Pharma INC | $48.69 | 2025 | Dyanavel Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $43.83 | 2024-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $37.22 | 2025 | Qelbree |
| Neos Therapeutics, LP | $31.35 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Idorsia Pharmaceuticals US INC | $19.56 | 2025 | Quviviq |
| Vanda Pharmaceuticals INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.